Journal
NEUROSCIENCE LETTERS
Volume 592, Issue -, Pages 37-41Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2015.02.055
Keywords
Spinocerebellar ataxia type 1; NMDA receptor; Memantine; Purkinje cells; Dorsal motor nucleus of vagus; Neurodegenerative disease
Categories
Funding
- Next Generation World-Leading Researchers [LS021]
- Japan Society for the Promotion of Science (JSPS)
- KAKENHI [25830046]
- Grants-in-Aid for Scientific Research [25830046] Funding Source: KAKEN
Ask authors/readers for more resources
Spinocerebellar ataxia type 1 (SCA1) is a progressive neurodegenerative disease caused by extension of a CAG repeat in the Sca1gene. Although the mechanisms underlying the symptoms of SCA1 have not been determined, aberrant neuronal activation potentially contributes to the neuronal cell death characteristic of the disease. Here we examined the potential involvement of extrasynaptic N-methyl-D-aspartate receptor (NMDAR) activation in the pathogenesis of SCA1 by administering memantine, a low-affinity noncompetitive NMDAR antagonist, in SCA1 knock-in (KI) mice. In KI mice, the exon in the ataxin 1 gene is replaced with abnormally expanded 154CAG repeats. Memantine was administered orally to the SCA1 KI mice from 4 weeks of age until death. The treatment significantly attenuated body-weight loss and prolonged the life span of SCA1 KI mice. Furthermore, memantine significantly suppressed the loss of Purkinje cells in the cerebellum and motor neurons in the dorsal motor nucleus of the vagus, which are critical for motor function and parasympathetic function, respectively. These findings support the contribution of aberrant activation of extrasynaptic NMDARs to neuronal cell death in SCA1 KI mice and suggest that memantine may also have therapeutic benefits in human SCA1 patients. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available